论文部分内容阅读
心律平是一种新型抗心律失常药物,具有强力的膜稳定作用,轻微的β阻滞作用,在体外有钙通道阻滞特性。本文报告心律平对于慢性室性心律失常长期治疗的安全性和持续疗效的临床经验。资料与方法:经心律平短期对照治疗有效并符合以下标准者列入研究:每小时室性早搏(室早)(VPCs)数减少85％或以上;每小时成对室早(VCs)减少95％或以上;每24小时室性心动过速(室速,VT)发作100％被消除。心律平与安慰剂双盲交叉试验选出24例;心律平与奎尼丁双盲对比研究选出
Cardiac Arrhythmias is a new type of anti-arrhythmic drug with strong membrane stabilizing effect and mild β-blockade, with calcium channel blockade in vitro. This article reports the clinical experience of long-term treatment of chronic ventricular arrhythmia with long-term efficacy and safety of heart rhythm. MATERIALS AND METHODS: Short-term prospective trials of cardioversion were included in the study and were included in the study. The number of premature ventricular contractions (VPCs) decreased by 85% or more per hour, and 95% reduction in premature ventricular contractions % Or more; 100% of the episodes of ventricular tachycardia (VT, VT) are eliminated every 24 hours. 24 cases were selected by double-blind crossover test between rhythm and placebo. Double-blind comparative study of ropivacaine and quinidine